COX-2 inhibitors are contraindicated for treatment of combined injury

Radiation Research

Volumn 172, Issue 6, 2009, Pages 686-697

  Jiao, W ^a   Kiang, J G ^a   Cary, L ^a   Elliott, T B ^a   Pellmar, T C ^a   Ledney, G D ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CELECOXIB; CYCLOOXYGENASE 2; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MELOXICAM; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CONTRAINDICATION; FEMALE; INFLAMMATION; LIVER TOXICITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RADIATION DOSE; RADIATION INJURY; WEIGHT GAIN; WOUND HEALING;

ANIMALS; BODY WEIGHT; CYCLOOXYGENASE INHIBITORS; CYTOKINES; DINOPROSTONE; FEMALE; MICE; PYRAZOLES; RADIATION INJURIES; SULFONAMIDES;

MUS;

EID: 70549111380     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1581.1     Document Type: Article

References (56)

1. G. D. Ledney, T. B. Elliott and M. M. Moore, Modulations of mortality by tissue trauma and sepsis in mice after radiation injury. In The Biological Basis of Radiation Protection Practice (K. L. Mossman and W. A. Mills, Eds.), pp. 202-217. Williams and Wilkins, Baltimore, 1992.
2. T. C. Pellmar and G. D. Ledney, Radiation in combination with trauma, infectious disease, or chemical exposure. In Radiation Bioeffects and Countermeasures (W. F. Blakely and C. F. Salter, Eds.), 19.1-19.9. AFRRI CD 05-102, Armed Forces Radiobiology Research Institute, Bethesda, MD, 2005.
3. A. L. DiCarlo, R. J. Hatchett, J. M. Kaminski, G. D. Ledney, T. C. Pellmar, P. Okunieff and N. Ramakrishnan, Medical countermeasures for radiation combined injury: radiation with burn, blast, trauma and/or sepsis. report of an NIAID Workshop, March 26-27, 2007. Radiat. Res. 169, 712-721 (2008).
4. C. N. Coleman, H. B. Stone, J. E. Moulder and T. C. Pellmar, Modulation of radiation injury. Science 304, 693-694 (2004).
5. F. Kojima, H. Naraba, Y. Sasaki, M. Beppu, H. Aoki and S. Kawai, Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. Arthritis Rheum. 48, 2819-2828 (2003).
6. Z. Lausevic, M. Lausevic, J. Trbojevic-Stankovic, S. Krstic and B. Stojimirovic, Predicting multiple organ failure in patients with severe trauma. Can. J. Surg. 51, 97-102 (2008).
7. Z. Zou, H. Sun, Y. Su, T. Cheng and C. Luo, Progress in research on radiation combined injury in China. Radiat. Res. 169, 722-729 (2008).
8. D. G. Jarrett, R. G. Sedlak, W. E. Dickerson and G. I. Reeves, Medical treatment of radiation injuries-Current US status. Radiat. Meas. 42, 1063-1074 (2007).
9. T. C. Pellmar and S. Rockwell, Priority list of research areas for radiological nuclear threat countermeasures. Radiat. Res. 163, 115-123 (2005)
10. K. L. Koenig, R. E. Goans, R. J. Hatchett, F. A. Mettler, Jr., T. A. Schumacher, E. K. Noji and D. G. Jarrett, Medical treatment of radiological casualties: current concepts. Ann. Emerg. Med. 45, 643-652 (2005).
11. I. Szumiel, Intrinsic radiation sensitivity: cellular signaling is the key. Radiat. Res. 169, 249-258 (2008).
12. S. Kyrkanides, A. H. Moore, J. A. Olschowka, J. C. Daeschner, J. P. Williams, J. T. Hansen and M. K. O'Banion, Cyclooxygenase-2 modulates brain inflammation-related gene expression in central nervous system radiation injury. Brain. Res. Mol. Brain. Res. 104, 159-169 (2002).
13. M. K. O'Banion, S. Kyrkanides and J. A. Olschowka, Selective inhibition of cyclooxygenase-2 attenuates expression of inflammation-related genes in CNS injury. Adv. Exp. Med. Biol. 507, 155-160 (2002).
14. A. Ueno and S. Oh-ishi, Critical roles for bradykinin and prostanoids in acute inflammatory reactions: a search using experimental animal models. Curr. Drug Targets Inflamm. Allergy 1, 363-376 (2002).
15. R. Boushel, H. Langberg, N. Risum and M. Kjaer, Regulation of blood flow by prostaglandins. Curr. Vasc. Pharmacol. 2, 191-197 (2004).
16. P. Patrignani, S. Tacconelli, M. G. Sciulli and M. L. Capone, New insights into COX-2 biology and inhibition. Brain Res. Brain Res. Rev. 48, 352-359 (2005).
17. R. M. Botting, Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J. Physiol. Pharmacol. 57 (Suppl. 5), 113-124 (2006).
18. W. F. Stenson, Prostaglandins and epithelial response to injury. Curr. Opin. Gastroenterol. 23, 107-110 (2007).
19. M. T. Wang, K. V. Honn and D. Nie, Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev. 26, 525-534 (2007).
20. W. Walker and D. Rotondo, Prostaglandin E2 is a potent regulator of interleukin-12-and interleukin-18-induced natural killer cell interferon-gamma synthesis. Immunology 111, 298-305 (2004).
21. K. Noguchi, M. Shitashige, H. Endo, H. Kondo and I. Ishikawa, Binary regulation of interleukin (IL)-6 production by EP1 and EP2/EP4 subtypes of PGE2 receptors in IL-1beta-stimulated human gingival fibroblasts. J. Periodontal Res. 37, 29-36 (2002).
22. M. Hofer, M. Pospisil, V. Znojil, J. Hola, A. Vacek, L. Weiterova, D. Streitova and A. Kozubik, Meloxicam, a cyclooxygenase 2 inhibitor, supports hematopoietic recovery in gamma-irradiated mice. Radiat. Res. 166, 556-560 (2006).
23. O. Messerschmidt, Combined effects of radiation and trauma. Adv. Space Res. 9, 197-201 (1989).
24. S. Zanotti and A. Kumar, Cytokine modulation in sepsis and septic shock. Expert Opin. Investig. Drugs 11, 1061-1075 (2002).
25. H. B. Stone, J. E. Moulder, C. N. Coleman, K. K. Ang, M. S. Anscher, M. H. Barcellos-Hoff, W. S. Dynan, J. R. Fike, D. J. Grdina and D. Zaharevitz, Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat. Res. 162, 711-728 (2004).
26. K. Muller and V. Meineke, Radiation-induced alterations in cytokine production by skin cells. Exp. Hematol. 35, 96-104 (2007).
27. V. K. Singh and V. S. Yadav, Role of cytokines and growth factors in radioprotection. Exp. Mol. Pathol. 78, 156-169 (2005).
28. F. Herodin and M. Drouet, Cytokine-based treatment of accidentally irradiated victims and new approaches. Exp. Hematol. 33, 1071-1080 (2005).
29. D. J. Berg, J. Zhang, D. M. Lauricella and S. A. Moore, Il-10 is a central regulator of cyclooxygenase-2 expression and prostaglandin production. J. Immunol. 166, 2674-2680 (2001). (Pubitemid 32173507)
30. W. H. Faour, Y. He, Q. W. He, M. de Ladurantaye, M. Quintero, A. Mancini and J. A. Di Battista, Prostaglandin E2 regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J. Biol. Chem. 276, 31720-31731 (2001).
31. H. Choy and L. Milas, Enhancing radiotherapy with cyclooxy-genase-2 enzyme inhibitors: a rational advance' J.Natl. Cancer Inst. 95, 1440-1452 (2003).
32. A. Bertolini, A. Ottani and M. Sandrini, Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol. Res. 44, 437-450 (2001).
33. R. W. McMurray and K. J. Hardy, Cox-2 inhibitors: today and tomorrow. Am J. Med. Sci. 323, 181-189 (2002).
34. J. van Ryn, G. Trummlitz and M. Pairet, COX-2 selectivity and inflammatory processes. Curr. Med. Chem. 7, 1145-1161 (2000).
35. J. van Ryn and M. Pairet, Clinical experience with cyclooxy-genase-2 inhibitors. Inflamm. Res. 48, 247-254 (1999).
36. P. Staerkel and Y. Horsmans, Meloxicam-induced liver toxicity. Acta Gastroenterol. Belg. 62, 255-256 (1999).
37. R. N. Dubois, S. B. Abramson, L. Crofford, R. A. Gupta, L. S. Simon, L. B. Van De Putte and P. E. Lipsky, Cyclooxygenase in biology and disease. FASEB J. 12, 1063-1073 (1998).
38. X. de Leval, F. Julemont, V. Benoit, M. Frederich, B. Pirotte and J. M. Dogne, First and second generations of COX-2 selective inhibitors. Mini Rev. Med. Chem. 4, 597-601 (2004).
39. A. Lenz, G. A. Franklin and W. G. Cheadle, Systemic inflammation after trauma. Injury 38, 1336-1345 (2007).
40. H. C. Pape, T. Tsukamoto, P. Kobbe, I. Tarkin, S. Katsoulis and A. Peitzman, Assessment of the clinical course with inflammatory parameters. Injury 38, 1358-1364 (2007).
41. M. Hofer, M. Pospisil, J. Hola, A. Vacek, D. Streitova and V. Znojil, Inhibition of cyclooxygenase 2 in mice increases production of G-CSF and induces radioprotection. Radiat. Res. 170, 566-571 (2008).
42. M. Hofer, M. Pospisil, V. Znojil, J. Hola, A. Vacek and D. Streitova, Meloxicam, an inhibitor of cyclooxygenase-2, increases the level of serum G-CSF and might be usable as an auxiliary means in G-CSF therapy. Physiol. Res. 57, 307-310 (2008).
43. M. R. Shurin, C. Esche and M. T. Lotze, FLT3: receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev. 9, 37-48 (1998).
44. A. Huchet, Y. Belkacemi, J. Frick, M. Prat, I. Muresan-Kloos, D. Altan, A. Chapel, N. C. Gorin, P. Gourmelon and J. M. Bertho, Plasma Flt-3 ligand concentration correlated with radiation-induced bone marrow damage during local fractionated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 57, 508-515 (2003).
45. A. Wodnar-Filipowicz, S. D. Lyman, A. Gratwohl, A. Tichelli, B.Speck and C. Nissen, Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood 88, 4493-4499 (1996). (Pubitemid 26419132)
46. M. Prat, C. Demarquay, J. Frick, N. Dudoignon, D. Thierry and J. M. Bertho, Use of Flt3 ligand to evaluate residual hematopoiesis after heterogeneous irradiation in mice. Radiat. Res. 166, 504-511 (2006).
47. I. Brook, T. B. Elliott, G. D. Ledney, M. O. Shoemaker and G. B. Knudson, Management of postirradiation infection: lessons learned from animal models. Mil. Med. 169, 194-197 (2004).
48. J. Suliburk, K. Helmer, F. Moore and D. Mercer, The gut in systemic inflammatory response syndrome and sepsis. Enzyme systems fighting multiple organ failure. Eur. Surg. Res. 40, 184-189 (2008).
49. E. A. Blomme, K. S. Chinn, M. M. Hardy, J. J. Casler, S. H. Kim, A. C. Opsahl, W. A. Hall, D. Trajkovic, K. N. Khan and C. S. Tripp, Selective cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. Br. J. Dermatol. 148, 211-223 (2003).
50. H. Kampfer, L. Brautigam, G. Geisslinger, J. Pfeilschifter and S. Frank, Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. J. Invest. Dermatol. 120, 880-890 (2003).
51. S. J. Laulederkind, S. Thompson-Jaeger, S. Goorha, Q. Chen, A. Fu, J. Y. Rho, L. R. Ballou and R. Raghow, Both constitutive and inducible prostaglandin H synthase affect dermal wound healing in mice. Lab. Invest. 82, 919-927 (2002).
52. W. C. Tsai, C. C. Hsu, S. W. Chou, C. Y. Chung, J. Chen and J. H. Pang, Effects of celecoxib on migration, proliferation and collagen expression of tendon cells. Connect. Tissue Res. 48, 46-51 (2007).
53. B. K. Reuter, S. Asfaha, A. Buret, K. A. Sharkey and J. L. Wallace, Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J. Clin. Invest. 98, 2076-2085 (1996).
54. A. Schmassmann, B. M. Peskar, C. Stettler, P. Netzer, T. Stroff, B. Flogerzi and F. Halter, Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br. J. Pharmacol. 123, 795-804 (1998).
55. K. Muller-Decker, W. Hirschner, F. Marks and G. Furstenberger, The effects of cyclooxygenase isozyme inhibition on incisional wound healing in mouse skin. J. Invest. Dermatol. 119, 1189-1195 (2002).
56. V. Lai, J. George, L. Richey, H. J. Kim, T. Cannon, C. Shores and M. Couch, Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck 30, 67-74 (2008).